NAS:RGNX (USA) Also trade in: Germany

Regenxbio Inc

$ 51.43 3.16 (6.55%)
Volume: 589,115 Avg Vol (1m): 571,066
Market Cap $: 1.88 Bil Enterprise Value $: 1.60 Bil
P/E (TTM): 0.00 P/B: 3.86
Earnings Power Value -238.23
Net Current Asset Value 7.48
Tangible Book 13.39
Projected FCF 0
Median P/S Value 64.21
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
68.09% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
RGNX: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.47, Med: 10000, Max: 10000
Current: 10000
0.47
10000
Equity-to-Asset 0.94
Equity-to-Asset ranked higher than
91.87% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
RGNX: 0.94
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -5.24, Med: 0.94, Max: 0.98
Current: 0.94
-5.24
0.98
Debt-to-EBITDA -0.13
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
RGNX: -0.13
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.65, Med: -0.29, Max: 0.06
Current: -0.13
-0.65
0.06
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 31.68
DISTRESS
GREY
SAFE
Beneish M-Score -3.19
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -45.39%
WACC 7.34%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -57.28
Operating Margin ranked higher than
95.20% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
RGNX: -57.28
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1423.84, Med: -191.37, Max: 40.32
Current: -57.28
-1423.84
40.32
Net Margin % -41.99
Net Margin ranked higher than
95.45% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
RGNX: -41.99
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1372.13, Med: -194.56, Max: 45.74
Current: -41.99
-1372.13
45.74
ROE % -8.67
ROE ranked higher than
96.46% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
RGNX: -8.67
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -42.45, Med: -28.63, Max: 28.89
Current: -8.67
-42.45
28.89
ROA % -8.19
ROA ranked higher than
97.23% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
RGNX: -8.19
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -214.62, Med: -35.68, Max: 26.92
Current: -8.19
-214.62
26.92
ROC (Joel Greenblatt) % -205.57
ROC (Joel Greenblatt) ranked higher than
97.20% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
RGNX: -205.57
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -8472.49, Med: -988.22, Max: 412.85
Current: -205.57
-8472.49
412.85
3-Year Total Revenue Growth Rate 206.50
3-Year Revenue Growth Rate ranked lower than
62.21% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
RGNX: 93.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -27.8, Med: -9.2, Max: 93.2
Current: 93.2
-27.8
93.2

» RGNX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:RGNX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2836
Compare HKSE:01681 SZSE:000518 NAS:ATNX NAS:MRTX NAS:GERN SHSE:603896 NYSE:BHVN SZSE:300255 NAS:AMRN SAU:2070 XPAR:GNFT SZSE:300149 XKRX:102940 SZSE:300204 HKSE:06826 SZSE:002872 SZSE:300147 XKRX:005690 TSE:4593 NAS:NTLA
Traded in other countries RB0.Germany
Address 9600 Blackwell Road, Suite 210, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

Ratios

Current vs industry vs history
Price-to-Owner-Earnings 2333.66
Price-to-Owner-Earnings ranked lower than
100.00% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
RGNX: 2333.66
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 1908.67, Med: 2430, Max: 2695
Current: 2333.66
1908.67
2695
PB Ratio 3.86
PB Ratio ranked lower than
68.92% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
RGNX: 3.86
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.07, Med: 3.19, Max: 8.07
Current: 3.86
1.07
8.07
PS Ratio 21.74
PS Ratio ranked lower than
53.03% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
RGNX: 21.74
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 6.35, Med: 27.2, Max: 129.6
Current: 21.74
6.35
129.6
Price-to-Free-Cash-Flow 380.33
Price-to-Free-Cash-Flow ranked higher than
59.87% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
RGNX: 380.33
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 14.94, Med: 30.52, Max: 439.19
Current: 380.33
14.94
439.19
Price-to-Operating-Cash-Flow 101.90
Price-to-Operating-Cash-Flow ranked higher than
56.19% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
RGNX: 101.9
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 13.1, Med: 27.19, Max: 127.45
Current: 101.9
13.1
127.45
EV-to-EBIT -32.11
EV-to-EBIT ranked lower than
57.47% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
RGNX: -32.11
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -37.5, Med: -5.7, Max: 35.6
Current: -32.11
-37.5
35.6
EV-to-EBITDA -35.39
EV-to-EBITDA ranked lower than
60.85% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
RGNX: -35.39
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -41.5, Med: -5.75, Max: 34.1
Current: -35.39
-41.5
34.1
EV-to-Revenue 18.37
EV-to-Revenue ranked higher than
55.51% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
RGNX: 18.37
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -33.8, Med: 28.45, Max: 110.6
Current: 18.37
-33.8
110.6
Current Ratio 14.21
Current Ratio ranked higher than
88.45% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
RGNX: 14.21
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.33, Med: 14.45, Max: 40.6
Current: 14.21
0.33
40.6
Quick Ratio 14.21
Quick Ratio ranked higher than
88.55% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
RGNX: 14.21
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.33, Med: 14.45, Max: 40.6
Current: 14.21
0.33
40.6
Days Sales Outstanding 35.12
Days Sales Outstanding ranked higher than
96.26% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
RGNX: 35.12
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 3, Med: 32.31, Max: 102.75
Current: 35.12
3
102.75
Days Payable 211.33
Days Payable ranked higher than
82.28% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
RGNX: 211.33
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 121.06, Med: 292.67, Max: 1032
Current: 211.33
121.06
1032

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -11.70
3-Year Share Buyback Rate ranked lower than
77.13% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
RGNX: -11.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -33.5, Med: -26.3, Max: -11.7
Current: -11.7
-33.5
-11.7

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.83
Price-to-Tangible-Book ranked lower than
61.63% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
RGNX: 3.83
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.08, Med: 3.04, Max: 7.3
Current: 3.83
1.08
7.3
Price-to-Median-PS-Value 0.80
Price-to-Median-PS-Value ranked higher than
90.56% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
RGNX: 0.8
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.25, Med: 1.19, Max: 4.02
Current: 0.8
0.25
4.02
Earnings Yield (Joel Greenblatt) % -3.14
Earnings Yield (Greenblatt) ranked higher than
86.22% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
RGNX: -3.14
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -34.1, Med: -10.1, Max: 30.2
Current: -3.14
-34.1
30.2

More Statistics

Revenue (TTM) (Mil) $ 87
EPS (TTM) $ -1.04
Beta 1.07
Volatility % 57.67
52-Week Range $ 38.56 - 85.1
Shares Outstanding (Mil) 36.64

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N